Bonifaz A, Araiza J, Baños-Segura C, Ponce-Olivera RM

Language: Spanish
References: 23
Page: 188-193
PDF size: 179.95 Kb.

ABSTRACT

Background: seborrheic dermatitis (sd) affecting the scalp (capitis) is a clinical entity of multifactorial etiology characterized by the presence of erythema, pruritus and oily scales, often associated with an increase of lipophilic yeast Malassezia, the therapeutic management is primarily with topical antifungals and keratolytic agents.
Objective: to compare two treatment regimens for the management of sd capitis with ciclopiroxolamine based shampoo + zinc pyrithione + keluamida (cpo/pz/k).
Material and methods: patients with sd of the scalp (capitis) were divided into two groups, both treated with shampoo cpo/pz/k, for group 1: applied three times per week for one month, and group 2: applied the first week daily and for the next three weeks, three times per weekly, with a 1-month follow-up. Clinical and mycological evaluations (observation of yeast, isolation and identification) were performed.
Results: the study included 39 patients, 20 in the first group and 19 in the other group. The average age of 24.5 years; 22/39 (56.41%) were male and 17/39 (43.6%) were female. The main predominant etiologic agent was M. globosa 34/39 (87.2%). When comparing both schemes, we observed a decrease of signs and symptoms during the first week of treatment, group 2 presented a significant reduction of clinical data, and also of Malassezia (12% vs. 8%), offering faster results during the first week of treatment, which allows better adherence to treatment.

REFERENCES

1. Dessinioti, C. y Katsambas, A., “Seborrheic dermatitis: etiology, risk factors, and treatments: facts and controversies”, Clin Dermatol, 2013, 31: 343-351.

2. Kim, G.K. y Rosso, J., “Topical pimecrolimus 1% cream in the treatment of seborrheic dermatitis”, J Clin Aesthet Dermatol, 2013, 6: 29-35.

3. Ramos-E-Silva, M., Sampaio, A.L. y Carneiro, S., “Red face revisited: Endogenous dermatitis in the form of atopic dermatitis and seborrheic dermatitis”, Clin Dermatol, 2014, 32: 109-115.

4. Zarei-Mahmoudabadi, A., Zarrin, M. y Mehdinezhad, F., “Seborrheic dermatitis due to Malassezia species in Ahvaz, Iran”, Iran J Microbiol, 2013, 5: 268-269.

5. Ooi, E.T. y Tidman, M.J., “Improving the management of seborrheic dermatitis”, Practitioner, 2014, 258: 23-26.

6. Trznadel-Grdzka, E., Blaszkowski, M. y Rotsztejn, H., “Investigations of seborrheic dermatitis. Part I. The role of selected cytokines in the pathogenesis of seborrheic dermatitis”, Postepy Hig Med Dosw (en línea), 2012, 66: 843-847.

7. Won Lee, Y., Yung Lee, S., Lee, Y. y Hee Jung, W., “Evaluation of expression of lipases and phospholipases of Malassezia restricta in patients with seborrheic dermatitis” Ann Dermatol, 2013, 3: 310-314.

8. Sampaio, A.L., Porto, L.C., Ramos-E-Silva, M., Nunes, A.P., Cardoso- Oliveira, J., Fabricio-Silva, G.M. et al., “Human leucocyte antigen frequency in a miscegenated population presenting with seborrhoeic dermatitis”, J Eur Acad Dermatol Venereol, 2014 (3 de febrero), doi: 10.1111/jdv.12373

9. Turlier, V., Viode, C., Durbise, E., Bacquey, A., LeJeune, O. et al., “Clinical and biochemical assessment of maintenance treatment in chronic recurrent seborrheic dermatitis: randomized controlled study” Dermatol Ther, 2014, 4: 43-59.

10. Goldust, M., Rezaee, E., Raghifar, R. y Hemayat, S., “Treatment of seborrheic dermatitis: the efficiency of sertaconazole 2% cream vs. Tacrolimus 0.03% cream”, Ann Parasitol, 2013, 59: 73-77.

11. Schwartz, R.A., Janusz, C.A., Janniger, R.A., “Seborrheic dermatitis: an overview”, Am Fam Physician, 2006, 74: 125-132.

12. Gupta, A.K. y Nicol, K.A., “Ciclopirox 1% shampoo for the treatment of seborrheic dermatitis”, Int J Dermatol, 2006, 45: 66-69.

13. Goldenberg, G.. “Optimizing treatment approaches in seborrheic dermatitis”, J Clin Aesthet Dermatol, 2013, 6: 44-49.

14. Shuster, S., Meynadier, J., Kerl, H. y Nolting, S., “Treatment and prophylaxis of seborrheic dermatitis of the scalp with antipityrosporal 1% ciclopirox shampoo”, Arch Dermatol, 2005, 141: 47-52.

15. Yu, R.K., Jeong-Hwan, K., Hong-Ju, S., Yong, B.C., Kyu, J.A. y Yang, W.L., “Clinical evaluation of a new-formula shampoo for scalp seborrheic dermatitis containing extract of Rosa centifolia petals and epigallocatechin gallate: a randomized, double-blind, controlled study”, Ann Dermatol, 2014, 6: 733-738.

16. Seite, S., Rougier, A. y Talarico, S., “Randomized study comparing the efficacy and tolerance of a lipohydroxy acid shampoo to a ciclopiroxolamine shampoo in the treatment of scalp seborrheic dermatitis”, J Cosmet Dermatol, 2009, 8: 249-253.

17. Ratnavel, R.C., Squire, R.A. y Boorman, G.C., “Clinical efficacies of shampoos containing ciclopirox olamine (1.5%) and ketoconazole (2.0%) in the treatment of seborrhoeic dermatitis”, J Dermatolog Treat, 2007, 18: 88-96.

18. Roques, D., Brousse, S. y Panizzutti, C., “In vitro antifungal efficacy of ciclopirox olamina alone and associated with zinc pyrithione compared to ketoconazole against Malassezia globosa and Malassezia restrica reference strains”, Mycopathologia, 2006, 162: 395-400.

19. Lorette, G. y Ermosilla, V., “Clinical efficacy of a new ciclopiroxolamine/ zinc pyrithione shampoo in scalp seborrheic dermatitis treatment”, Eur J Dermatol, 2006, 16: 558-564.

20. Gupta, A.K., Nicol, K. y Batra, R., “Role of antifungal agents in the treatment of seborrheic dermatitis”, Am J Clin Dermatol, 2004, 5: 417-422.

21. Schlesinger, T. y Rowland Powell, C., “Efficacy and safety of a low molecular weight hyaluronic Acid topical gel in the treatment of facial seborrheic dermatitis final report”, J Clin Aesthet Dermatol, 2014, 7: 15-18.

22. Ratnavel, R.C., “Clinical efficacies of shampoos containing ciclopirox olamine (1.5%) and ketoconazole (2.0%) in the treatment of seborrhoeic dermatitis”, J Dermatolog Treat, 2007, 18: 88-96.

23. Ayhan, M., Sancak, B., Karaduman, A., Arikan, S. y Sahin, S., “Colonization of neonate skin by Malassezia species: relationship with neonatal cephalic pustulosis”, J Am Acad Dermatol, 2007, 57: 1012-1018.